Medical societies unite on patient-centered measures for nonsurgical stroke interventions

FAIRFAX, Va.—The first outcome-based guidelines for interventional treatment of acute ischemic stroke—providing recommendations for rapid treatment—will benefit individuals suffering from brain attacks, often caused by artery-blocking blood clots. Representatives from the Society of Interventional Radiology and seven other medical societies created a multispecialty and international consensus on the metrics and benchmarks for processes of care and technical and clinical outcomes for stroke patients.

In February, the guidelines will be published first in SIR’s Journal of Vascular and Interventional Radiology and subsequently by each society either in its respective journal or on its website.

“These groundbreaking guidelines are the product of two years of collaboration among multidisciplinary teams from eight societies,” said Marshall E. Hicks, M.D., FSIR, president of the Society of Interventional Radiology, the national society of nearly 5,000 doctors, scientists and allied health professionals dedicated to improving health care through minimally invasive treatments. “With real progress being made in research and treatment of stroke over the last decade, this distinguished group of international authors—from societies whose members perform minimally invasive stroke treatments—felt that the time was right for a consensus on how to effectively treat and manage stroke patients,” said Hicks, the head of the division of diagnostic imaging at the University of Texas MD Anderson Cancer Center in Houston. source: Society of Interventional Radiology

Society of Interventional Radiology: Time to rethink varicose veins

FAIRFAX, Va., Feb. 6, 2013 /PRNewswire-USNewswire/ -- The Society of Interventional Radiology, an international organization of doctors, scientists and allied health professionals dedicated to improving public health through minimally invasive, image-guided treatments, joined as a member of the "Rethink Varicose Veins" coalition, an alliance of organizations united to drive public awareness of the risks of varicose veins and chronic venous insufficiency.

"Becoming part of this wide-reaching initiative supports the Society of Interventional Radiology's mission to improve public health through advances in minimally invasive medicine," said SIR President Marshall E. Hicks , M.D., FSIR, who represents the society's nearly 5,000 doctors, scientists and allied health professionals. "The contributions of interventional radiologists—doctors who are specially trained in performing minimally invasive treatments using imaging guidance, and experts in the treatment of venous insufficiency—to this kind of outreach program are invaluable," said Hicks, the head of the division of diagnostic imaging at the University of Texas MD Anderson Cancer Center in Houston. "SIR is committed to developing and maintaining the highest standards of excellence in patient care. Together with the other societies involved, we are pleased to be a part of this campaign to alert the public to the dangers of varicose veins and venous disease," said Hicks.

source: PR Newswire

Medical societies to launch large-scale study on vein filter use

FAIRFAX, Va., Feb. 1, 2013 /PRNewswire-USNewswire/ -- The Society of Interventional Radiology and Society for Vascular Surgery jointly will launch PRESERVE—the first large-scale, multispecialty prospective study to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment.

The study—along with the formation of the IVC Filter Study Group Foundation—are direct actions taken to address the August 2010 FDA medical alert detailing the possibility that retrievable IVC filters could move or break, potentially causing significant health risks for patients. SIR and SVS are in the process of determining a framework for the PRESERVE (PREdicting the Safety and Effectiveness of InferioR VEna Cava Filters) study, with the goal of obtaining a functional view of all filters placed in the United States.

"PRESERVE data will allow a systematic, functional view, representative of all filters placed in the United States, thus, all stakeholders—individuals, health care professionals, insurers and government regulators—will be armed with the knowledge they need on patient risk and, subsequently, quality improvement in filter placement, management and retrieval," said SIR President Marshall E. Hicks, M.D., FSIR. "This is a paradigm-shifting initiative: interventional radiologists and vascular surgeons collaborating to launch a large-scale prospective study evaluating inferior vena cava filters reveals a lot about each specialty's focus—and that focus is on patients, first and foremost," noted SVS President Peter Gloviczki, M.D.

source: PRnewswire

Siemens 3-D Angiography Imaging Software Cleared by FDA

Malvern, Pa., February 16, 2012 – Siemens Healthcare recently received clearance from the U.S. Food and Drug Administration (FDA) for syngo Aortic ValveGuide, an integrated image processing software that helps cardiologists and cardiac surgeons prepare and perform transcatheter aortic valve replacement (TAVR). The syngo Aortic ValveGuide automatically reconstructs a 3D representation of the aortic root from cross-sectional images acquired with the angiography system and provides the best projection angle for the valve replacement. The software selects anatomical landmarks and overlays the 3D image with 2D images acquired during live fluoroscopy, enabling the physician to obtain real-time 3D guidance in the patient’s body while navigating the new valve to its intended location. This groundbreaking software, which is now available to customers, reflects the spirit of Siemens Healthcare’s Agenda 2013 – a recently announced two-year initiative designed in part to strengthen the Healthcare Sector's innovative power and competitiveness.

During the minimally invasive TAVR intervention, an artificial aortic valve is inserted via the femoral artery or through the apex of the heart. syngo Aortic ValveGuide provides the physician with automated 3D guidance by segmenting the aortic root in 3D mode from images created using the angiography system. With the aid of anatomical landmarks in the 3D vessel representation, syngo Aortic ValveGuide calculates the exact perpendicular view on the aortic root. The C-arm adjusts to the corresponding angulations for live fluoroscopy, enabling the physician to precisely position the new valve. Consequently, as soon as the software overlays the 3D image of the aorta with the 2D live fluoroscopy, the cath lab cardiologist – or, respectively, the heart surgeon in the hybrid OR – can begin the intervention.

source: Siemens Medical

Society of Interventional Radiology Foundation Receives Support From Siemens Medical

Corporate Pledge of $200,000 Supports Major Fund-raising Initiative to Expand Minimally Invasive Medicine Into New Areas of Discovery

FAIRFAX, Va., Dec. 20, 2011 /PRNewswire-USNewswire/ -- The Society of Interventional Radiology Foundation's Discovery Campaign, which seeks to further the growth of minimally invasive medicine into new areas of discovery, announced a major corporate pledge to that initiative. Siemens Medical Solutions, a provider of imaging and laboratory diagnostic equipment and information technology and management consulting and services to health care customers, pledged $200,000, as a "Pioneer" Supporter.

"The impact that corporate support at this level has on the future of the specialty is immense," said Gordon McLennan, M.D., FSIR, chair of the SIR Foundation board of directors. "The funding will be used to support grants, research consensus panels, registries, clinical trials and educational programming. Support of this kind sends a clear message about investing in the future of interventional radiology, a truly trailblazing specialty," noted McLennan, an interventional radiologist with the Cleveland Clinic in Cleveland, Ohio. "We thank Siemens Medical Solutions for coming forward to support us on this venture," he noted.

"We are dedicated to supporting educational and research initiatives and developing technologies to advance image-guided therapies," noted Claus Grill, vice president of Siemens Medical Solutions, USA Inc., based in Malvern, Pa.

source: PR Newswire

GE Healthcare Introduces Innova* IGS 630 Biplane Interventional Imaging System with Next Generation of 3D, Advanced Applications

CHICAGO — November 29, 2011 — Today at RSNA 2011, GE Healthcare (NYSE: GE) introduced the Innova IGS 630[i] biplane cardiovascular and interventional imaging system. The system features Innova CT HD[ii], which brings 3D to the next level, and a comprehensive set of advanced applications for interventional neuroradiology. It also offers peace of mind through our comprehensive dose management solutions and an enhanced end user experience for optimized workflow through customized display possibilities. These features are of particular importance in interventional neuroradiology procedures, which uses minimally invasive image-based technologies to help physicians diagnose and treat diseases of the central nervous system, head, neck and spine.

“The Innova IGS 630 biplane reflects our strong clinical focus and commitment to understanding the unique needs of each clinical specialty. With this introduction, we offer a new generation of 3D imaging, new options and advanced applications that truly cater to interventional neuroradiology procedures,” said Chantal Le Chat, general manager of GE Healthcare Interventional Radiology.

source: GE Medical

IVC Filters: Society of Interventional Radiology Leads in Patient Care, Safety, Research

FAIRFAX, Va., Nov. 28, 2011 /PRNewswire-USNewswire/ -- Researchers have published the largest single patient population study to date on a method for following patients with retrievable inferior vena cava (IVC) filters—devices used to keep blood clots from traveling to the lungs. This study, which is important for individuals with IVC filters and their doctors, supports existing guidelines developed by the Society of Interventional Radiology, a national organization of nearly 4,700 doctors, scientists and allied health professionals dedicated to improving health care through minimally invasive treatments.

Results from this IVC filter study reinforce SIR's existing guidelines surrounding either successful retrieval or permanent placement," said SIR President Timothy P. Murphy, M.D., FSIR. "SIR knows that this is an important and vigorously debated issue. This research—an important addition to the inferior vena cava filter discussion—supports the call for continued rigorous patient/doctor communication and detailed data collection throughout the process, especially after filter placement in order for there to be success," noted Murphy, an interventional radiologist and director of the Vascular Disease Research Center at Rhode Island Hospital in Providence. "Research like this may also provide a framework that doctors can use to guide practice and treat patients safely," he added.

source: PR Newswire

BK Medical Introduces Flex Focus 700 Ultrasound System With Interventional Radiology Capabilities at the ECR

PEABODY, Mass., March 2, 2011 (GLOBE NEWSWIRE) -- BK Medical, a wholly owned subsidiary of Analogic Corporation (Nasdaq:ALOG), introduces its new Flex Focus™ 700 ultrasound system and BK Power Pack with dedicated interventional radiology capabilities. The Flex Focus 700 and the BK Power Pack will be demonstrated at the European Congress of Radiology (ECR), March 3-7, 2011, in booth #632.

The Flex Focus 700 is a premium performance ultrasound system designed for interventional radiology, internal medicine, and general imaging. The system has been very well received since its initial introduction for surgery, where BK Medical is a global leader. The new BK Power Pack is a full back-up power solution for the Flex Focus family of ultrasound systems that ensures plug-free imaging for up to four hours, allowing improvements to workflow and potential reductions in patient wait times. The Flex Focus 700 is the latest in the award-winning Flex Focus family series of innovative ultrasound systems, which includes the Flex Focus 200, the Flex Focus 400, and the newly released Flex Focus 400 Anesthesia.

source: GloveNewswire

GE Healthcare Announces Two New Vascular Visualization Software Applications for Interventional Procedures at ECR

Unique, innovative visualizations enable radiologists to make better decisions during image-guided interventions

Vienna, Austria; March 4, 2011: At the European Congress of Radiology in Vienna, Austria, this week, GE Healthcare introduced two new vascular visualization software applications that give interventional radiologists more complete, detailed information. FlightPlan for Liver automatically extracts vessels in the vicinity of the tumor during liver embolizations, while AngioViz enhances Digital Subtraction Angiography (DSA) to give a new vision of vascular flow.

“We are proud to offer our customers new information they will find incredibly valuable when planning and assessing complex interventional procedures. FlightPlan is a unique and truly innovative application, and represents a major breakthrough in liver embolization. And AngioViz takes the DSA technique to a new level,” said Chantal Le Chat, General Manager of Interventional Radiology, GE Healthcare.

source: GE Healthcare

NCRP Report Available: Report No. 168 - Radiation Dose Management for Fluoroscopically-Guided Interventional Medical Procedures

This Report is focused on the use of fluoroscopic systems as a tool for guiding diagnostic and therapeutic procedures because higher radiation doses (compared to conventional radiography and fluoroscopy) are received regularly from some types of FGI procedures and occasionally from many other types of FGI procedures. Other medical applications of fluoroscopy (e.g., examination of the gastrointestinal system, guiding open surgical procedures) are outside the scope of this Report. Computed-tomography-guided interventional (CTGI) procedures are not discussed in detail due to continuing changes in the technology driven by the evolution of multi-slice computed tomography (CT) detectors. However, the principles presented in this Report are generally applicable to these domains. Most of the recommendations contained in this Report should be applied in all settings where fluoroscopic guidance is used.

report available form: NCRP Publications

Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System

New system integrates market-leading Renegade HI-FLO Microcatheter with high-torque Fathom-16 Steerable Guidewire for peripheral embolization procedures

NATICK, Mass., Jan. 31, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved its Renegade® HI-FLO™ Fathom® Pre-Loaded System for selective access and delivery of diagnostic, embolic and therapeutic materials into the peripheral vasculature. The system will primarily be used by interventional radiologists for minimally invasive procedures to treat uterine fibroids and liver cancer. The Company said it plans to launch the product immediately in the United States.

The Renegade HI-FLO Fathom Pre-Loaded System combines the turn-for-turn torque response, flexibility and high visibility of the Fathom-16 Steerable Guidewire with the clinically proven performance of the Renegade HI-FLO Microcatheter, pre-loaded in a single convenient platform. The system will be available in eight configurations to suit a broad range of peripheral embolization procedures.

"The excellent deliverability, torque transmission and flow capacity of the Renegade HI-FLO Fathom Pre-Loaded System provides physicians with the performance they need to efficiently access tortuous vessels across many types of interventional oncology procedures," said Jeff Geschwind, M.D., Professor of Radiology, Surgery and Oncology, and Director of Vascular and Interventional Radiology at the Johns Hopkins University School of Medicine.

source: PR Newswire

Journal Of Vascular And Interventional Radiology Debuts New Look, Reflects Global Impact

The Journal of Vascular and Interventional Radiology-the monthly, peer-reviewed flagship publication of the Society of Interventional Radiology-announced several major changes for 2011-all directed at highlighting the global impact of this minimally invasive medical specialty and its lead journal. JVIR, which has been published since 1989, focuses on critical and cutting-edge medical, minimally invasive, radiological, pathological and socioeconomic issues of importance to vascular and interventional radiologists.

"Changes have been made to further enhance the Journal of Vascular and Interventional Radiology's core strengths, particularly to streamline its editorial process. My target goal is 30 days for time to first decision for new manuscripts," said new editor-in-chief Ziv J Haskal, M.D., FSIR. "JVIR is a vigorous engine for rapid peer review and delivery of the most novel and impactful, global, cutting-edge, basic science research, clinical reports and evidence-based medicine-JVIR aims to build on that legacy," explained Haskal, professor of radiology and surgery at the University of Maryland School of Medicine and vice chair of strategic development and chief of vascular and interventional radiology, image-guided therapy and interventional oncology at the University of Maryland Medical Center, both in Baltimore, Md.

source: SIR

Results from CIRSE Multicenter Registry Reinforce Safety of St. Jude Medical Vascular Closure Device

ST. PAUL, Minn., Dec 09, 2010 (BUSINESS WIRE) --

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, commends the efforts of the investigators in the CIRSE Vascular Closure Device Registry, the world's first multicenter registry aimed at assessing the performance of vascular closure devices in interventional radiology (IR) procedures.

With more than 1,100 patients enrolled at 28 centers in 10 European countries, the CIRSE registry validated the routine use of Angio-Seal(TM) vascular closure devices in IR, with successful deployment achieved in approximately 97 percent of procedures. The registry was conducted under the leadership of Principal Investigator Jim A. Reekers, M.D., Ph.D., professor of interventional radiology at the University of Amsterdam, The Netherlands, and confirmed that the use of Angio-Seal vascular closure devices in IR procedures is safe and effective with low incidence of serious complications.

"The CIRSE Vascular Closure Device Registry results provide physicians with an unbiased source of information that verifies the benefits of closure devices in interventional radiology procedures," said Dr. Reekers. "The results offer strong clinical data that demonstrate the use of Angio-Seal vascular closure devices are safe and effective with outstanding deployment success rates."

source: ST. Jude Medical

Toshiba's New Volume Navigation 3D Roadmap Facilitates More Accurate Visualization During Complex Interventions

During complex interventional procedures, it is challenging to accurately navigate and interpret the vascular anatomy for precise device deployment. To aid physicians during such interventions, Toshiba America Medical Systems, Inc., has introduced Volume Navigation 3D roadmapping for the InfinixTM-i vascular X-ray product line, providing greater confidence during difficult interventional procedures.

Toshiba's real-time Volume Navigation 3D roadmap displays the deployment of coils during intervention on a cerebral aneurysm with exceptional clarity and precision. Volume Navigation links the movements of the system components with the fusion 3D and fluoroscopic display, so despite changes in even table and C-arm position, the 3D overlay is automatically aligned with the fluoroscopic image with high accuracy. In addition, Volume Navigation provides 2D and 3D roadmap display modes and allows physicians to fine-tune images with manual controls for device enhancement, further assisting physicians when making difficult decisions during advanced procedures. Volume Navigation is particularly helpful for procedures on intricate vascular regions, such as the brain, uterus and abdominals.

source: Toshiba Medical

Society of Interventional Radiology Press Offers New Edition of Patient Care Resource

"Patient Care in Vascular and Interventional Radiology" - an essential resource and the first offering from Society of Interventional Radiology Press, the society's publishing arm - is now available. Also available is the companion "Patient Care in Vascular and Interventional Radiology Study Guide."

Written by top experts in their areas of specialty, this resource is ideal for physicians in their fellowship or in training, for certification or recertification or for those who want to brush up on crucial areas of patient care. The newly updated 448-page edition of SIR's popular syllabus covers major aspects such as vascular, neurologic, hepatobiliary, cardiac, pulmonary and genitourinary evaluation; management of hypertension, renal insufficiency, hematologic disorders, antiobiotics, analgesia and sedation, cardiopulmonary emergencies, vascular complications, liver and renal failure, postprocedural pain and nutrition; and postprocedural wound management. The spiral-bound book includes detailed tables and charts for handy reference, figures for illustration and bibliographies for further reading. Its compact size and spiral binding make it easy to carry for on-the-go learning.

source: SIR

Bleeding Risk Associated with Image-Guided Biopsies is Low

Even among patients who have taken aspirin in proximity to an image-guided percutaneous biopsy, risk of major bleeding associated with the procedure is low, according to a study in the March issue of the American Journal of Roentgenology (www.ajronline.org). Image-guided percutaneous biopsies are an important means of diagnosing disease in organs and other soft tissues. They involve the removal of cells or tissues for examination.

“With the evolution of imaging guidance, percutaneous biopsy has become a valuable tool in obtaining tissue for diagnosis,” said Thomas D. Atwell, MD, lead author of the study. “Unfortunately, this procedure is not without risk, and hemorrhage is the most feared complication after biopsy,” he said.

The study included a retrospective review of percutaneous biopsies performed at the Mayo Clinic in Rochester, MN, over the course of six years. “Among the 15,181 percutaneous biopsies performed during the study period, only 70 hemorrhages (0.5 percent) were identified within three months of biopsy,” said Atwell. “The incidence of bleeding in patients taking aspirin within 10 days before biopsy was 0.6 percent (18/3,195),” he said.

“Our study shows that the overall incidence of major bleeding after imaging-guided percutaneous needle biopsy is low, and recent aspirin therapy does not appear to significantly increase the risk of such bleeding complications,” said Atwell.

source: ARRS

Society Of Interventional Radiology Supports Treatment For Painful Spine Fractures: Patient Selection Key

Given the current controversy over vertebroplasty -- a minimally invasive treatment performed by interventional radiologists in individuals with painful osteoporotic vertebral compression fractures that fail to respond to conventional medical therapy -- what's a patient to do? Trust your medical team to decide if you are an appropriate candidate for vertebroplasty and trust the experience of hundreds of thousands of other patients who have undergone the spine treatment successfully and received life-improving effects, says the Society of Interventional Radiology.

"Hundreds of thousands of patients have greatly benefited from vertebroplasty with almost complete resolution of their pain; tens of thousands dependent on intravenous narcotics have been discharged from the hospital virtually pain- and drug-free following their treatment," noted SIR President Brian F. Stainken, M.D., FSIR, who represents the national organization of nearly 4,500 doctors, scientists and allied health professionals dedicated to improving health care through minimally invasive treatments. "Before treatment, many of these osteoporotic patients are in constant pain and cannot manage everyday activities. Many are confined to bed for up to six weeks. These are the people we help; with vertebroplasty they can go home in one to two days. Candidates for the procedure are those who have failed to respond to conventional medical treatment (such as rest, analgesics and narcotic drugs).

source: SIR

When Seconds Count: Interventional Radiology Treatment for Pulmonary Embolism Saves Lives

FAIRFAX, Va./PRNewswire-USNewswire/ -- Catheter-directed therapy or catheter-directed thrombolysis--an interventional radiology treatment that uses targeted image-guided drug delivery with specially designed catheters to dissolve dangerous blood clots in the lungs--saves lives and should be considered a first-line treatment option for massive pulmonary embolism, note researchers in the November Journal of Vascular and Interventional Radiology.

"Modern catheter-directed therapy for acute pulmonary embolism saves lives, and we need to raise awareness about its safety and effectiveness not only among the general public but also within the medical community. It's a matter of life and death," said William Kuo, M.D., an interventional radiologist who is assistant professor and fellowship director of vascular and interventional radiology in the Department of Radiology at Stanford University Medical Center in Stanford, Calif. "In our study, we conclude that modern catheter-directed therapy is a relatively safe and effective treatment for acute massive pulmonary embolism and should be considered as a first-line treatment option," he added.

Pulmonary embolism occurs when one or more arteries in the lungs become blocked from blood clots that break free and travel there. These clots most often begin as deep vein thrombosis (DVT) or blood clots within the deep leg veins. When the clots break free, circulate and become trapped in the lungs, they can block the oxygen supply, cause heart failure and result in death. About 600,000 cases of acute pulmonary embolism are diagnosed each year in the United States, and an estimated 300,000 patients die, noted Kuo. "If initiated early, minimally invasive catheter-directed therapy could save many of those lives," added the lead author of the study, "Catheter-directed Therapy for the Treatment of Massive Pulmonary Embolism: Systematic Review and Meta-analysis of Modern Techniques."

source: PR Newswire

GE Healthcare and Veran Medical Technologies Announce Imaging and Navigation Collaboration for Interventional Procedures at RSNA 2009

CHICAGO, ILLINOIS – December 1, 2009 – Today, GE Healthcare, a $17 billion unit of General Electric Company (NYSE: GE), and Veran Medical Technologies, Inc., announced that they have collaborated to validate the compatibility of the Veran ig4 Navigation system and GE Innova® imaging systems for use in the imaging suites during interventional procedures. The announcement was made at the Radiological Society of North America (RSNA) 2009 meeting in Chicago, Ill.

Veran ig4 is a multi-modality navigation system that utilizes electromagnetic localization and image fusion to display an interventional instrument, such as a biopsy needle, an aspiration needle, or an ablation needle, on a computer monitor that also displays a CT-based model of the target organ(s). GE’s Innova imaging systems acquire computerized tomography (CT)-like patient images, which under the terms of the collaboration agreement, can be exported to the Veran ig4 Navigation system in the same imaging suite, during the same interventional procedure. The Innova CT image will be displayed along with a virtual needle over the anatomy to be used for navigation during the procedure. The resulting displayed image will provide navigation information to help physicians insert biopsy needles, ablation (RF, cryotherapy, and microwave) probes and other devices through the skin more quickly and with greater target accuracy. “This can help speed procedures, freeing procedure room time and improving access to care while enhancing quality of care. We anticipate this collaboration will help clinicians to achieve greater accuracy, perform procedures more quickly and potentially reduce radiation dose to patients,” Jayant Saha, General Manager, Strategic Interventional Market Development for GE Healthcare.

source: GE Healthcare

Sentinelle Medical and Siemens AG Collaborating on Solutions for Interventional Prostate MRI

TORONTO, Nov. 30 /PRNewswire/ - Sentinelle Medical Inc., a leading manufacturer of breast MRI coils and software, and Siemens Healthcare today announced at the Radiological Society of North America (RSNA) annual meeting in Chicago, that they are collaborating on the development of a suite of innovative solutions for Interventional Prostate MRI.

According to the American Cancer Society, Prostate cancer will affect close to 200,000 men and cause 27,000 deaths this year (2009) in the US. Current screening technologies are limited in their ability to reliably detect prostate cancer. Prostate MRI shows significant promise to address these challenges. However, initial offerings offer limited signal-to-noise ratios (SNR) coverage for the prostate, and current interventional solutions lack the ability to combine with internal imaging coils.

Sentinelle and Siemens are working together to develop solutions that will address the challenges clinicians currently face in the use of MRI for imaging, intervention and treatment of prostate cancer. These solutions will address image quality, ease and accuracy of intervention, patient experience and workflow efficiency - all critical elements in the widespread adoption of prostate MRI. Sentinelle will be demonstrating Works-In-Progress for Prostate interventional MRI coils at RSNA 2009 (Booth 5800, Hall A).

"Prostate imaging provides unique challenges for imaging and intervention. Siemens and Sentinelle are dedicated to delivering solutions that can be easily integrated into the clinicians workflow, and positively impact patient outcomes," said Cameron Piron, Sentinelle's President and CEO. "With our combined focus, we are confident that we can address these challenges and enable greater access to this important technology."

source: PR Newswire